Staurosporine enhanced benzamide riboside-induced apoptosis in human multidrug-resistant promyelocytic leukemia cells (HL-60/VCR) in vitro

Neoplasma

Volumn 45, Issue 4, 1998, Pages 204-209

  Hunakova L ^a   Duraj, J ^a   Romanova D ^a   Novotny L ^a,d   Sedlak J ^a   Kelley, M R ^c   Szekeres, T ^b   Jayaram, H N ^c   Chokvath B ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INDIANA UNIVERSITY   (United States)

^d KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Apoptosis; Benzamide riboside; Drug resistant; Flow cytometry; Human leukemia cells; MDR 1; P glycoprotein; Staurosporine

Indexed keywords

BENZAMIDE DERIVATIVE; STAUROSPORINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROMYELOCYTIC LEUKEMIA;

EID: 0031791963     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. BERGAMASCHI, G., ROSTI, V., DANOVA, M., PONCHIO, L., LUCOTTI, C., CAZZOLA, M.: Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemia cell lines. Leukemia, 7, 1993, 2012-2018.
2. CHORVATH, B., SEDLÁK, J.: Protein kinase inhibitors: Drug-resistance modulation and induction of apoptosis in neoplastic cell lines. Neoplasma, 43, 1996, 3-7.
3. CHORVÁTH, B., SEDLÁK, J., NOVOTNÝ, L.: The protein kinase C inhibitor, CGP 41 251 reverses decreased daunomycine uptake in a human drug-resistant ovarian carcinoma cell line. Int. J. Cancer, 59, 1994, 852-853.
4. COULDWELL, W. T., HINTON, D. R., HE, S., CHEN, T. C., SEBAT, L., WEISS, M. H., LAW, R.E.: Protein kinase C inhibitor induce apoptosis in human malignant glioma cell lines. FEBS Lett., 23, 1994, 43-46.
5. FALCIERI, E., MARTELLI, A.M., BAREGI, R., CATALDI, A., COCCO, L.: The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-cells without concomitant DNA fragmentation. Biochem. Biophys. Res. Commun., 28, 1993, 19-25.
6. GHAREHBAGHI, K., PAULL, K.D., KELLEY, J.A., BARCHI, J.J., MARQUEZ, V.E., COONEY, D.A., MONKS, A., SCUDIERO, D., KROHN, K., JAYARAM, H.N.: Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.Int. J. Cancer, 56, 1994, 892-899.
7. GHAREHBAGHI, K.,SCREENATH, A., HAO, Z., PAULL, K.D., SZEKERES, T., COONEY, D.A., KROHN, K., JAYARAM, H.N.:Comparison of biochemical parameters of benzamide riboside, a new inhibitor IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem. Pharmacol., 48, 1994, 1413-1419.
8. GRANT, S., TURNER, A.J., BARTIMOLE, T.N., NELMS, P.A., JOE, V.C., JARVIS, W.D.: Modulation of 1 -(ß-D-arabinofuranosyl) cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncol. Res., 6, 1994, 87-99.
9. HIRSCH, T., MARCHETTI, P., SUSIN, S. A., DALLAPORTA, B., ZAMZAMI, N., MARZO, I., GEUSKENS, M., KROEMER, G.: The apoptosis - necrosis paradox: Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene, 15, 1997, 1573-1581.
10. HUNÁKOVÁ, L., ŠULIKOVÁ, M., DURAJ, J., SEDLÁK, J., CHORVÁTH, B.: Stimulation of 1-(beta-D-arabinofuranosyl) cytosine (AraC)-induced apoptosis in the multidrug-resistant human promyelocytic leukemia cell lines with protein kinase inhibitors. Neoplasma, 43, 1996, 291-294.
11. HUNÁKOVÁ, L., SEDLAK, J., ŠULIKOVÁ, M., CHOVANCOVÁ, J., CHORVÁTH, B.: Human multidrug-resistant ( MRP, p190) myeloid leukemia HL-60/ADR cells in vitro: Resistance to the mevalonate pathway inhibitor lovastatin. Neoplasma, 44, 1997, 366-469.
12. HOLMBERG, M., SANDBERG, C., NYGREN, P., LARSSON, R.: Effects of lovastatin on human myeloma cell line: Increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs, 5, 194, 598-600.
13. JALAVA, A., AKERMAN, K., HEIKKILA, J.: Protein kinase inhibitor staurosporine, induces a mature neuronal phenotype in SHSYS 5 human neuroblastoma cells through alpha-, beta-, and zeta-protein kinase C-independent pathway J. Cell Physiol., 155, 1993, 301-312.
14. JARVIS, W.D., TURNER, A.J., POVIRK, L.F., TRAYLOR, R.S., GRANT, S.: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res., 54, 1994, 1707-1714.
15. JAYARAM, H.N., GHAREHBAGHI, K., JAYARAM, N.H., RIESER, J., KROHN, K., PAULL, K.D.: Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells. Biochem. Biophys. Res. Commun., 186, 1992, 1600-1606.
16. KROHN, K., HEINS, H., WIELCKENS, K.: Synthesis and cytotoxicity of C-glycosidic nicotinamide riboside analogues. J. Med. Chem., 35, 1992, 511-517.
17. LAREDO, J., HUYNH, A., MULLER, C., JAFFREZOU J. P., BAILLY, J. D., CASSAR, G., LAURENT, G., DEMUR C.: Effect of protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood, 84, 1994, 229-237.
18. LIU, X., KIM, C.N., YANG, J., JEMMERSON, R., WANG, X.: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell, 86, 1996, 147-157.
19. MARSH, W., SICHERI, D., CENTER, M.S.: Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial accumulation of drug. Cancer Res., 46, 1996, 4053-4057.
20. McGRATH, T., LATOUD, C., ARNOLD, S.T., SAFA, A.R., FELSTED, R.L., CENTER, M.S.: Mechanisms of multidrug resistance in HL-60 cells: Analysis of resistance associated membrane proteins and levels of MDR gene expression.Biochem. Pharmacol., 38, 1989, 3611-3619.
21. MEDINA, V., EDMONDS,B., YOUNG, G.P., JAMES, R., ALETON, S., ZALEWSKI, P.: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Depedence on protein synthesis and synergy with a mitochondrial cytochrome c-dependent pathway.Cancer Res., 57, 1997, 3697-3707.
22. SAUNDERS, P. P., ARIMILLI, S., KROHN, K., MUHS, M., ALVAREZ, E., SURVELYER, R.: Metabolism and action of benzamide riboside in chineses hamster ovary cells. Anticancer Drugs, 7, 1996, 93-99.
23. SEDLÁK, J., HUNAKOVÁ, L., DURAJ, J., CHORVÄTH, B., NOVOTNÝ, L.: Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anti-Cancer Drugs, 6, 1995,70-76.
24. SEDLAK, J., HUNÁKOVÁ, L., ŠULIKOVÁ, M., CHORVÁTH, B.: Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia (HL-60) cells. Leukemia Res., 21, 1997, 449-458.
25. WEBER, G., SHEN, F., PRAJDA, N., YEH Y. A., YANG, H., HERENYIOVA, M., LOOK, K. Y.: Increased signal transduction activity and down-regulation in human cancer cells. Anticancer Res., 16, 1996, 3271-3282.
26. WEBER, G. SHEN, F., PRAJDA, N., YANG, H., LI, W., ZEH, A., CSOKAY, B., OLAH, E., LOOK, K. Y.: Regulation of the signal transduction program by drugs. Adv. Enzyme Regul., 37, 1997, 35-55.
27. ZAMZAMI, N., SUSIN, S.A., MARCHETTI, P., HIRSCH, T., GOMEZ-MONTEREY, I., CASTEDO, M. KROEMER, G.: Mitochondrial control of nuclear apoptosis. J. Exp. Med., 183, 1996, 1533-1544.
28. ZIMMERMANN, A., KELLER, H.: Effects of staurosporine, K252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. Br. J. Cancer, 66, 1992, 1077-1082.